Seven voted. Six recommended. Nothing is legal yet.

What the committee actually decided

On 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A Bulk Drug Substances List, the roster of raw ingredients a licensed compounding pharmacy may legally use when making a prescription for one named patient.

Each peptide was voted twice, once as free base and once as the acetate salt, for fourteen voting questions in total. Every peptide broke identically across both forms.

These were medical votes, not wellness votes

This is the detail the viral version leaves out, and it is the one most likely to matter to you later. The committee did not vote on "gut health" or "longevity." Each peptide was reviewed against a specific medical indication, and a prescriber will eventually have to write one of these on a real prescription.

A committee weighing BPC-157 for an inflammatory bowel disease is not a committee blessing it for general recovery. Those are different questions with different evidence bars, and the gap between the two columns above is where a lot of disappointment is going to live.

What changed on the day of the vote: nothing

An advisory committee recommends. FDA decides. To actually add a substance, the agency has to review the record, publish a proposed rule, open a comment period, weigh the comments, and publish a final rule. Reporting puts that at up to a year, and rulemaking routinely runs longer.

FDA is free to decline. Given that its own reviewers said no to all seven, declining is a live possibility rather than a technicality.

The part almost everyone has wrong

A lot of people in this space believe the legal question was already settled in the spring. It was not, and the real sequence matters.

So the current position is a gap: not expressly prohibited, not authorized. If you have been operating since spring on the belief that reclassification already happened, that belief rests on a promise that was never executed.

The agency's own scientists said no to all seven

Not some. All. FDA's briefing documents concluded that none of the seven met the four-factor framework the agency uses, citing missing human safety data, no universally agreed chemical specification, batch-to-batch inconsistency, and for injectables a risk of immune reactions driven by aggregation and peptide-related impurities.

The most quoted moment of the two days came from Russell Wesdyk, the Associate Director for Regulatory Affairs in CDER's Office of Product Quality Assessment, who put the identity problem in terms anyone can follow.

That is not a bureaucratic complaint. It is the observation that two vials labelled TB-500 may not contain the same molecule, which is precisely the problem a compounding pharmacy cannot solve on its own.

What a listing would actually buy you

Say FDA eventually lists them. That is much narrower than "peptides are legal now."

Listing lets a state-licensed pharmacy use the bulk ingredient to make a preparation against a valid prescription written for a specific, named patient. It does not authorize retail sale of vials. It does not make the peptide an approved drug. It does not let anyone sell you a vial without a prescriber. And it does not retroactively legalize any existing grey vendor's business model.

There is also a supply problem nobody is discussing. A 503A pharmacy must source bulk ingredient from an FDA-registered facility with proper documentation. Most of what circulates today is research-grade material from Chinese suppliers, a chain with no quality infrastructure and no ability to recall a contaminated batch. A listing on paper does not put product on a shelf.

What it does to cost

Two tiers exist today. The figures below are indicative market ranges drawn from commercial sources rather than audited survey data, and they should be read as orders of magnitude rather than quotes.

The gap is three to seven times, and legalization probably does not close it, because the markup is not in the molecule.

Pharmaceutical-grade ingredient runs roughly three to five times research-grade, and that multiplier is driven by documentation, testing and quality systems rather than purity itself. Three to five times on an ingredient is not what turns sixty dollars a month into six hundred. The prescriber visit, the membership, the clinic wrapper and the recurring-revenue model do that.

Compounded NAD+ is the closest comparison available, a non-approved sterile injectable sold cash-pay through longevity clinics. The vial runs fifty to two hundred dollars while monthly programs run one hundred fifty to four hundred, at doses a thousand times larger than a peptide dose. The milligrams are not what you are paying for.

There is real evidence on the cheaper side too. Compounded semaglutide undercut the brand by five to seven times while it was legal. Compounded low-dose naltrexone runs twenty to sixty dollars a month and compounded HCG fifty-three to eighty-three per 10,000 IU. A sanctioned channel does not inherently carry a premium.

What this does to the people selling, and to you buying

Start with the thing that gets repeated most and is most wrong. "Research use only" has never been a legal shield. Under federal law a product is a drug based on its intended use, and FDA establishes intended use from website copy, social posts and surrounding circumstances, not from the disclaimer. FDA's warning letters to peptide sellers say it plainly: the evidence from the website establishes the products are intended as drugs for human use. Selling bacteriostatic water alongside the vials is treated as further evidence of human-use intent.

That enforcement is neither theoretical nor new.

Read that timeline again, because it undercuts both confident narratives. The grey market was already consolidating hard under enforcement pressure with no legal alternative in sight. This vote did not start that.

Two forces, pulling opposite ways

The case that it shrinks. The single best argument grey vendors and their customers have used is "there is no legal way to get this." For these six molecules specifically, that argument dies. A US-based vendor with a brand, a website, a payment processor and identifiable owners is now competing against a licensed channel while remaining an easy target, and we have already watched that exact vendor archetype break.

The case that it grows. This was the largest free advertising event these compounds have ever had, reaching millions who had never heard of BPC-157. The price gap survives legalization. Buyers face no criminal exposure. FDA's headcount did not change. And critically, these six have no brand-name manufacturer with a patent to defend, so the wave of private lawsuits strangling grey GLP-1 sellers has no equivalent here. Nobody is going to sue a BPC-157 vendor for infringing a product that does not exist.

My read is bifurcation rather than a clean win or loss. The visible, branded, US-facing vendor loses. The offshore and anonymous seller does fine. The total number of people injecting these compounds goes up.

If you sell in this space, the risk is not that demand vanishes. It is that being findable becomes the liability.

And spare a thought for the one that lost

Emideltide, which is DSIP, is now in a worse position than if it had never been reviewed. Before 24 July a seller could point to regulatory silence. Now there is a documented FDA review and an advisory committee that declined to recommend it, in the same session where six siblings got through. The same logic extends to every peptide never nominated: a short blessed list creates an implied unblessed list, and everything outside it reads as more clearly illicit than it did when nothing was blessed.

The problem the vote does not fix

If you take one practical thing from this page, take this.

The grey market's entire trust apparatus is the certificate of analysis, and the COA measures the one thing that is usually fine. In independent aggregate testing of BPC-157 across hundreds of samples from dozens of vendors, HPLC purity came back consistently high. Fill quantity diverged from the advertised amount by as much as seventy-one percent. You can hold a genuine 99 percent purity COA for a vial containing a fraction, or a large excess, of what the label says.

The sterility test is almost never run, and the reason is structural rather than lazy: nobody can hold inventory for fourteen days and still run that business.

For a sense of what this means in practice, a peer-reviewed 2024 analysis of semaglutide bought from online sellers without a prescription found measured purity between 7.7 and 14.37 percent against a 99 percent label claim, and detected endotoxin in every single sample. Different compound, same supply chain, same incentives.

That is the honest case for a legal channel independent of price: a named prescriber who owns the dose, a pharmacist who checks your other medications, a lot number, a beyond-use date, a recall pathway, and somewhere to go when something goes wrong.

Who voted, and what they do for a living

This is public-record information about people acting in a public capacity, and it is the part worth reading closely if you want to know whose judgment to trust. Every financial tie below was reported by a named outlet. Serving on the committee is not wrongdoing, and a disclosed interest is not a bribe. The point is not to accuse anyone. It is that you can now see the pattern for yourself.

The split tracks professional background closely. Most reported "yes" votes came from clinicians who work with peptides directly. Most reported "no" votes came from academic and hospital specialists who do not.

That pattern is real, and it has two honest readings. You can call it a conflict, which is what several outlets did. You can equally call it expertise: the people who prescribe these compounds every week have watched patients take them, and the people voting no mostly had not. A committee of pure academics would have its own blind spot. Which reading you find persuasive is a judgment call, and this page is not going to make it for you.

What the record does not show is anyone voting yes because they were paid to. No source establishes that, FDA's ethics screening issued no conflict-of-interest waivers under the relevant federal statute, and correlation between someone's job and their vote is not proof of motive. Treat the tables as information about who was in the room, not as an accusation.

It also matters that the yes side made a substantive argument, not a commercial one. Their case was that the legal standard for adding a bulk substance under section 503A is not the standard for approving a new drug, and that refusing access pushes people toward an unregulated supply that is measurably worse. Read the next section before deciding what you think, because the argument in the room was better than the argument online.

Two caveats on the tables themselves: individual votes were only reported for some members, and David Pope voted yes on BPC-157 with no reported peptide-selling practice, so the pattern is strong rather than perfect. No vote was inferred from anyone's employer. The one member who abstained throughout, Timothy Fensky, represents the National Association of Boards of Pharmacy, which took no position.

In their own words

The transcript is more interesting than any summary of it, because both sides made a real argument. Here is the actual exchange.

The case for yes: harm reduction

The yes side did not argue the evidence was good. They argued that people are already injecting this, and that a regulated version is safer than what is being bought now.

And the detail that says the most about the whole proceeding: one member described the data as "frankly disappointed at how incomplete the data was" and voted yes anyway.

The case for no: we do not know what this is

FDA's position, stated as plainly as it can be

From the public comment session

Roughly 1,860 comments were filed to the docket. The line of the two days came from a Georgetown pharmacology professor, answering the harm-reduction argument head on.

Also testifying in favour: the chief medical officer of Hims & Hers, a publicly traded telehealth company positioned to sell compounded peptides, whose stock moved on the outcome. Both sides of this room had money in the answer. That is worth knowing when you read anyone's summary of it, including this one.

"They can't be patented" is the opposite of true

This is the load-bearing claim in the post that has been circulating, and it collapses on ten minutes of checking. Peptides are patented constantly. Five of these six have granted US patents you can pull up right now.

MOTS-c is also covered by University of Southern California filings from the laboratory that discovered it, and the IP was licensed to a biotech that took an analog into human trials. A specific patent number circulating for it did not verify against the public record, so it is deliberately not listed above.

So what is the real reason nobody developed them?

Here is the honest version of the argument the viral post is groping toward, because there is a real economic story. It is just not suppression.

A US patent runs twenty years from filing. Patents filed on these compounds in the late 1980s and 1990s have already expired or are close to it. An expired patent means anyone can make the molecule, which means no company can recoup the roughly one to two billion dollars and ten-plus years that FDA approval demands. The incentive is gone, not because a conspiracy removed it, but because the clock ran out.

There is a second reason, and the peer-reviewed literature names it directly. A 2026 review in Pharmaceutics concluded that the primary barrier to clinical translation is "the absence of fundamental pharmaceutical science: characterized formulations, validated pharmacokinetics, and a coherent drug development strategy." Not suppression. Missing homework.

And one detail that quietly refutes the whole conspiracy frame: a biotech did license the MOTS-c intellectual property and take an analog through early human trials. Somebody tried. The category is not forbidden. It is just hard, expensive, and unrewarding once the patent clock has run.

"Unpatentable" is a story that explains away missing evidence. The missing evidence is the actual problem.

Watch and read it yourself

Do not take my summary, or anyone's. The primary material is public.

Three honest conclusions

If you use these compounds: nothing changed this week. Do not let a headline talk you into treating a research vial as a blessed product, and do not let a seller cite this vote as cover. If a legal route opens, expect it to cost more per month and be worth considering anyway, because you are buying oversight and accountability rather than milligrams. If you are drug tested in any capacity, that calculation is stricter for you.

If you sell in this space: the exposure is on you, not your customers, and "research use only" is not the protection you have been told it is. The enforcement trend was already steep before this vote, and a blessed list makes everything off that list look worse.

For everyone: watch for the proposed rule. That document, not this vote, is the thing that actually changes your life, and the comment period is where public input carries weight.